All In Biotech

Drug Trial Radar · NCT07314346

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

A Phase 1, Open-Label, Two-Part, Single-Sequence Study to Evaluate the Effect of Multiple Oral Doses of BEM/RZR FDC on the Pharmacokinetics of Buprenorphine/Naloxone or Methadone in Participants on Stable Maintenance Therapy for Opiate Withdrawal

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 7, 2025

Primary completion

Jul 23, 2026

Study completion Jul 23, 2026

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

Conditions

  • Healthy Volunteer Study

Interventions

  • Buprenorphine/Naloxone + BEM/RZRDrug

    Day -5 to Day -1:buprenorphine/naloxone as individualized QD doses up to 24mg/6mg. Day 1 to Day 5:Individualized QD doses of buprenorphine/naloxone. Day 6 to Day 12:Individualized QD doses of buprenorphine/naloxone + BEM 550mg/RZR 180mg QD. Day 13 Individualized QD doses of buprenorphine/naloxone.

  • Methadone +BEM/RZRDrug

    Day -5 to Day -1:methadone individualized QD doses: 30-150mg. Day 1 to Day 5:Individualized QD does of methadone. Day 6 to Day 12:Individualized QD doses of methadone + BEM 550mg/RZR 180mg QD. Day 13 Individualized QD doses of methadone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of BEM/RZR on PK of buprenorphine,norbuprenorphine and naloxoneTime frame: Day -5 to Day 13
  2. Effect of BEM/RZR on PK of buprenorphine,norbuprenorphine and naloxoneTime frame: Day -5 to Day 13
  3. Effect of BEM/RZR on PK of methadoneTime frame: Day -5 to Day 13
  4. Effect of BEM/RZR on PK of methadoneTime frame: Day -5 to Day 13

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Atea Study Site

    Hollywood, Florida

  • Atea Study Site

    Overland Park, Kansas

  • Atea Study Site

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.